LUNGR - Overview: Lung Cancer Rearrangement Testing, Tumor

Test Catalog

Test Name

Test ID: LUNGR    
Lung Cancer Rearrangement Testing, Tumor

Useful For Suggests clinical disorders or settings where the test may be helpful

Identifying lung tumors that may respond to targeted therapies by simultaneously assessing multiple genes involved in rearrangements resulting in fusion transcripts

 

Diagnosis and management of patients with lung cancer

Genetics Test Information Provides information that may help with selection of the correct test or proper submission of the test request

This test uses next-generation sequencing to identify rearrangements (fusions) involving ALK, ROS1, RET, and NTRK1. See Activated/Partner Gene Breakpoints Resulting in Targeted Fusion Transcripts Interrogated by Lung Panel in Special Instructions for details regarding the targeted gene regions evaluated by this test.

 

Of note, this test is performed to evaluate rearrangements (fusions) within solid tumor samples. This test is not intended for use for hematological malignancies.

Highlights

Evaluates formalin-fixed, paraffin-embedded tumor or cytology slides from patients with lung cancer for rearrangements (fusions) to identify candidates for targeted therapy.

 

Current data suggests that lung carcinomas with ALK rearrangements may be sensitive to ALK inhibitors.

Additional Tests Lists test(s) that are always performed, at an additional charge, with the initial test(s)

Test IDReporting NameAvailable SeparatelyAlways Performed
SLIRVSlide Review in MGNo, (Bill Only)Yes

Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.

When this test is ordered, slide review will always be performed at an additional charge.

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test

Method Name A short description of the method used to perform the test

Polymerase Chain Reaction (PCR)-Based Next Generation Sequencing

(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

Lung Rearrangement Testing, Tumor

Aliases Lists additional common names for a test, as an aid in searching

ALK
ROS1
RET
NTRK1
Lung cancer rearrangement
Lung cancer fusion
Next Gen Sequencing Test
NGS